Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy

Abstract Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging. We therefore focused on developing nanobody-based CAR-T cells that treat the solid tumor. CD105 expre...

Full description

Bibliographic Details
Main Authors: Fengzhen Mo, Siliang Duan, Xiaobing Jiang, Xiaomei Yang, Xiaoqiong Hou, Wei Shi, Cueva Jumbo Juan Carlos, Aiqun Liu, Shihua Yin, Wu Wang, Hua Yao, Zihang Yu, Zhuoran Tang, Shenxia Xie, Ziqiang Ding, Xinyue Zhao, Bruce D. Hammock, Xiaoling Lu
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-021-00462-1

Internet

https://doi.org/10.1038/s41392-021-00462-1

Similar Items